The evolution of assays for immuno-oncology research
Drug Discovery World
FEBRUARY 15, 2023
Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6.
52 
Let's personalize your content